Cargando…

Plasma pooling in combination with amotosalen/UVA pathogen inactivation to increase standardisation and safety of therapeutic plasma units

OBJECTIVES: Assessment of the impact of pooling five single‐donor plasma (SDP) units to obtain six pathogen‐reduced therapeutic plasma (PTP) units on standardisation and the retention of labile coagulation factors. BACKGROUND: SDP shows a high inter‐donor variability with potential implications for...

Descripción completa

Detalles Bibliográficos
Autores principales: Bubinski, Michal, Gronowska, Agnieszka, Szykula, Pawel, Kluska, Kamila, Kuleta, Ilona, Ciesielska, Emilia, Picard‐Maureau, Marcus, Lachert, Elzbieta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048654/
https://www.ncbi.nlm.nih.gov/pubmed/33686720
http://dx.doi.org/10.1111/tme.12763
_version_ 1783679270438043648
author Bubinski, Michal
Gronowska, Agnieszka
Szykula, Pawel
Kluska, Kamila
Kuleta, Ilona
Ciesielska, Emilia
Picard‐Maureau, Marcus
Lachert, Elzbieta
author_facet Bubinski, Michal
Gronowska, Agnieszka
Szykula, Pawel
Kluska, Kamila
Kuleta, Ilona
Ciesielska, Emilia
Picard‐Maureau, Marcus
Lachert, Elzbieta
author_sort Bubinski, Michal
collection PubMed
description OBJECTIVES: Assessment of the impact of pooling five single‐donor plasma (SDP) units to obtain six pathogen‐reduced therapeutic plasma (PTP) units on standardisation and the retention of labile coagulation factors. BACKGROUND: SDP shows a high inter‐donor variability with potential implications for the clinical treatment outcome. Additionally, there is still an existing risk for window‐period transmissions of blood borne pathogens including newly emerging pathogens. METHODS/MATERIALS: Five ABO‐identical SDP units were pooled, treated with the INTERTCEPT™ Blood System (Cerus Corporation, U.S.A.) and split into six PTP units which were frozen and thawed after 30 days. The variability in volume, labile coagulation factor retention and activity was assessed. RESULTS: The variability of volumes between the PTP units was reduced by 46% compared to SDP units. The variability in coagulation factor content between the PTP units was reduced by 63% compared to SDP units. Moderate, but significant losses of coagulation factors (except for vWF) were observed in PTPs compared to SDPs. CONCLUSION: The pooling of five SDP units to obtain six PTP units significantly increases product standardisation with potential implications for safety, economics as well as transfusion‐transmitted pathogen safety, making it an interesting alternative to quarantine SDP (qSDP) and pathogen‐reduced SDP.
format Online
Article
Text
id pubmed-8048654
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-80486542021-04-19 Plasma pooling in combination with amotosalen/UVA pathogen inactivation to increase standardisation and safety of therapeutic plasma units Bubinski, Michal Gronowska, Agnieszka Szykula, Pawel Kluska, Kamila Kuleta, Ilona Ciesielska, Emilia Picard‐Maureau, Marcus Lachert, Elzbieta Transfus Med Short Communications OBJECTIVES: Assessment of the impact of pooling five single‐donor plasma (SDP) units to obtain six pathogen‐reduced therapeutic plasma (PTP) units on standardisation and the retention of labile coagulation factors. BACKGROUND: SDP shows a high inter‐donor variability with potential implications for the clinical treatment outcome. Additionally, there is still an existing risk for window‐period transmissions of blood borne pathogens including newly emerging pathogens. METHODS/MATERIALS: Five ABO‐identical SDP units were pooled, treated with the INTERTCEPT™ Blood System (Cerus Corporation, U.S.A.) and split into six PTP units which were frozen and thawed after 30 days. The variability in volume, labile coagulation factor retention and activity was assessed. RESULTS: The variability of volumes between the PTP units was reduced by 46% compared to SDP units. The variability in coagulation factor content between the PTP units was reduced by 63% compared to SDP units. Moderate, but significant losses of coagulation factors (except for vWF) were observed in PTPs compared to SDPs. CONCLUSION: The pooling of five SDP units to obtain six PTP units significantly increases product standardisation with potential implications for safety, economics as well as transfusion‐transmitted pathogen safety, making it an interesting alternative to quarantine SDP (qSDP) and pathogen‐reduced SDP. Blackwell Publishing Ltd 2021-03-08 2021-04 /pmc/articles/PMC8048654/ /pubmed/33686720 http://dx.doi.org/10.1111/tme.12763 Text en © 2021 The Authors. Transfusion Medicine published by John Wiley & Sons Ltd on behalf of British Blood Transfusion Society. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communications
Bubinski, Michal
Gronowska, Agnieszka
Szykula, Pawel
Kluska, Kamila
Kuleta, Ilona
Ciesielska, Emilia
Picard‐Maureau, Marcus
Lachert, Elzbieta
Plasma pooling in combination with amotosalen/UVA pathogen inactivation to increase standardisation and safety of therapeutic plasma units
title Plasma pooling in combination with amotosalen/UVA pathogen inactivation to increase standardisation and safety of therapeutic plasma units
title_full Plasma pooling in combination with amotosalen/UVA pathogen inactivation to increase standardisation and safety of therapeutic plasma units
title_fullStr Plasma pooling in combination with amotosalen/UVA pathogen inactivation to increase standardisation and safety of therapeutic plasma units
title_full_unstemmed Plasma pooling in combination with amotosalen/UVA pathogen inactivation to increase standardisation and safety of therapeutic plasma units
title_short Plasma pooling in combination with amotosalen/UVA pathogen inactivation to increase standardisation and safety of therapeutic plasma units
title_sort plasma pooling in combination with amotosalen/uva pathogen inactivation to increase standardisation and safety of therapeutic plasma units
topic Short Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048654/
https://www.ncbi.nlm.nih.gov/pubmed/33686720
http://dx.doi.org/10.1111/tme.12763
work_keys_str_mv AT bubinskimichal plasmapoolingincombinationwithamotosalenuvapathogeninactivationtoincreasestandardisationandsafetyoftherapeuticplasmaunits
AT gronowskaagnieszka plasmapoolingincombinationwithamotosalenuvapathogeninactivationtoincreasestandardisationandsafetyoftherapeuticplasmaunits
AT szykulapawel plasmapoolingincombinationwithamotosalenuvapathogeninactivationtoincreasestandardisationandsafetyoftherapeuticplasmaunits
AT kluskakamila plasmapoolingincombinationwithamotosalenuvapathogeninactivationtoincreasestandardisationandsafetyoftherapeuticplasmaunits
AT kuletailona plasmapoolingincombinationwithamotosalenuvapathogeninactivationtoincreasestandardisationandsafetyoftherapeuticplasmaunits
AT ciesielskaemilia plasmapoolingincombinationwithamotosalenuvapathogeninactivationtoincreasestandardisationandsafetyoftherapeuticplasmaunits
AT picardmaureaumarcus plasmapoolingincombinationwithamotosalenuvapathogeninactivationtoincreasestandardisationandsafetyoftherapeuticplasmaunits
AT lachertelzbieta plasmapoolingincombinationwithamotosalenuvapathogeninactivationtoincreasestandardisationandsafetyoftherapeuticplasmaunits